Evidence map›Paper›PMID 35625319›Full record

ArticleAntibiotics (Basel, Switzerland)2022

The Class A β-Lactamase Produced by

Scott A Becka, Elise T Zeiser, John J LiPuma, Krisztina M Papp-Wallace

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. The oral penems and carbapenems.Clinical microbiology reviews · 2025
    Review
  2. Article
  3. Evaluation of aJournal of oral microbiology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Scott A BeckaResearch Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.
Elise T ZeiserResearch Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.
John J LiPumaDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Krisztina M Papp-WallaceResearch Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.ORCID 0000-0002-9976-7898
VA Northeast Ohio Healthcare System · USUniversity of Michigan · US

Funding

Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–
BLRD VA I01 BX002872Cystic Fibrosis Foundation NASpero Therapeutics (United States) NAUnited States Department of Veterans Affairs BX002872
6 · The paper itself

Abstract

Tebipenem-pivoxil hydrobromide, an orally bioavailable carbapenem, is currently in clinical development for the treatment of extended-spectrum β-lactamase- and AmpC-producing Enterobacterales. Previously, tebipenem was found to possess antimicrobial activity against the biothreat pathogens,

Indexed as

AmpCBurkholderiacarbapenemcarbapenemasePenAtebipenemβ-lactamβ-lactamase

Identifiers

PMID35625319
PMCPMC9137479
OpenAlexW4280608619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.